Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25762540 | 0.94 | HTT (0.47) | HTT | |
| SCHEMBL30453122 | 0.90 | PRCP (0.46) | NPSR1PREPTSHRL3MBTL1KMT2A | |
| SCHEMBL30511007 | 0.85 | OPRD1 (0.49) | NPSR1PREPTSHRL3MBTL1KMT2A | |
| SCHEMBL30452094 | 0.85 | MEN1 (0.45) | NPSR1PREPHTTKMT2A | |
| SCHEMBL25766939 | 0.85 | ACE2 (0.52) | NPSR1PREPTSHRL3MBTL1KMT2A | |
| SCHEMBL25449146 | 0.84 | PRMT5 (0.47) | NPSR1HTTKMT2APRMT5FKBP1A | |
| SCHEMBL12496208 | 0.82 | FKBP1A (0.52) | PRMT5FKBP1A | |
| SCHEMBL13567882 | 0.82 | PREP (0.47) | NPSR1PREPTSHRL3MBTL1KDM4E | |
| SCHEMBL7303935 | 0.82 | PRCP (0.51) | NPSR1PREPHTTTSHRL3MBTL1 | |
| SCHEMBL9037209 | 0.82 | KLK7 (0.51) | PREPHTTKMT2AACE2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440700-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | NPSR1 4454/4885PREP 901/4885HTT 3181/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | NPSR1 4454/4885PREP 901/4885HTT 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.